EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its President and CEO, Jay S. Duker, M.D., will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th, 2025, at 9:10 a.m. ET.

During the presentation, EyePoint will provide an enrollment update for its ongoing DURAVYU™ Phase 3 pivotal program in wet age-related macular degeneration (wet AMD). Additionally, the company will share additional subgroup analyses from the Phase 2 VERONA clinical trial of DURAVYU in diabetic macular edema (DME).

The presentation will be available via live webcast with an archived replay accessible through the Investors section of EyePoint's website at www.eyepointpharma.com. EyePoint is focused on developing and commercializing innovative therapeutics for patients with serious retinal diseases.

– Company presentation scheduled on Tuesday, March 4^th at 9:10am ET –

– EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup analyses from Phase 2 VERONA clinical trial in DME –

WATERTOWN, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., EyePoint’s President and CEO, will present an update on enrollment for its ongoing Phase 3 pivotal program of DURAVYU in wet age-related macular degeneration (wet AMD) and additional subgroup analyses for the Phase 2 VERONA trial for DURAVYU in diabetic macular edema (DME) at the TD Cowen 45th Annual Health Care Conference.

• Cowen 45th Annual Health Care Conference
  Forum: Corporate Presentation
  Date: Tuesday, March 4, 2025
  Time: 9:10 a.m. ET

A live webcast and subsequent archived replay of each presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint

EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and recently completed a Phase 2 clinical trial in diabetic macular edema (DME). Based on positive Phase 2 results from the VERONA clinical trial in DME, EyePoint anticipates meeting with U.S. and ex-U.S. regulatory agencies in the second quarter of 2025 to confirm plans for a pivotal program.

Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert^® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com

Media Contact:

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

When will EyePoint Pharmaceuticals (EYPT) present at the TD Cowen Health Care Conference?

EyePoint Pharmaceuticals will present on Tuesday, March 4th, 2025, at 9:10 a.m. ET during the TD Cowen 45th Annual Health Care Conference.

What updates will EYPT share about the DURAVYU Phase 3 program at the March 2025 conference?

EyePoint will provide an enrollment update for its ongoing DURAVYU Phase 3 pivotal program in wet age-related macular degeneration (wet AMD).

What clinical trial data will EyePoint (EYPT) present about DURAVYU for diabetic macular edema?

EyePoint will present additional subgroup analyses from the Phase 2 VERONA clinical trial of DURAVYU in diabetic macular edema (DME).

How can investors access EyePoint's presentation at the TD Cowen conference in March 2025?

Investors can access a live webcast and subsequent archived replay of the presentation via the Investors section of EyePoint's website at www.eyepointpharma.com.

What retinal conditions is EyePoint Pharmaceuticals (EYPT) targeting with DURAVYU?

EyePoint is targeting wet age-related macular degeneration (wet AMD) with its Phase 3 program and diabetic macular edema (DME) as demonstrated in its Phase 2 VERONA trial.